Validating a biosignature-predicting placebo pill response in chronic pain in the settings of a randomized controlled trial.

ABSTRACT:

Abstract

The objective of this study is to validate a placebo pill response predictive model-a biosignature-that classifies chronic pain patients into placebo responders (predicted-PTxResp) and nonresponders (predicted-PTxNonR) and test whether it can dissociate placebo and active treatment responses. The model, based on psychological and brain functional connectivity, was derived in our previous study and blindly applied to current trial participants. Ninety-four chronic low back pain (CLBP) patients were classified into predicted-PTxResp or predicted-PTxNonR and randomized into no treatment, placebo treatment, or naproxen treatment. To monitor analgesia, back pain intensity was collected twice a day: 3 weeks baseline, 6 weeks of treatment, and 3 weeks of washout. Eighty-nine CLBP

SUBMITTER: Vachon-Presseau E 

PROVIDER: S-EPMC8863986 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature